Effect of thrombolysis on myocardial injury: Recombinant tissue plasminogen activator vs. alfimeprase

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 290, Issue 3, 2006, Pages

  Hong, Ting Ting ^a   Huang, Jinbao ^a   Lucchesi, Benedict R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Myocardium; Reperfusion injury; Thrombolytic agents

Indexed keywords

ALFIMEPRASE; ALTEPLASE; CRL 42796; FIBRINOGEN RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; FIBRINOLYTIC AGENT; METALLOPROTEINASE; RECOMBINANT PROTEIN; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY THROMBOSIS; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; CORONARY ARTERY CIRCUMFLEX BRANCH; DOG; FIBRINOLYSIS; HEART INFARCTION SIZE; HEART MUSCLE INJURY; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; REPERFUSION; ANIMAL; COMPARATIVE STUDY; CONVALESCENCE; DRUG EFFECT; FIBRINOLYTIC THERAPY; GENETICS; METHODOLOGY; REPERFUSION INJURY; TREATMENT OUTCOME;

ANIMALS; DOGS; FIBRINOLYTIC AGENTS; METALLOENDOPEPTIDASES; MYOCARDIAL REPERFUSION INJURY; RECOMBINANT PROTEINS; RECOVERY OF FUNCTION; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 33645749928     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00649.2005     Document Type: Article

References (44)

1. Agostoni A, Gardinali M, Frangi D, Cafaro C, Conciato L, Sponzilli C, Salvioni A, Cugno M, and Cicardi M. Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction. A comparison between streptokinase and recombinant tissue-type plasminogen activator. Circulation 90: 2666-2670, 1994.
2. Ahmed NK, Gaddis RR, Tennant KD, and Lacz JP. Biological and thrombolytic properties of fibrolase - a new fibrinolytic protease from snake venom. Haemostasis 20: 334-340, 1990.
3. Angeja BG, Gunda M, Murphy SA, Sobel BE, Rundle AC, Syed M, Asfour A, Borzak S, Gourlay SG, Barron HV, Gibbons RJ, and Gibson CM. TIMI myocardial perfusion grade and ST segment resolution: association with infarct size as assessed by single photon emission computed tomography imaging. Circulation 105: 282-285, 2002.
4. Aronson DL, Chang P, and Kessler CM. Platelet-dependent thrombin generation after in vitro fibrinolytic treatment. Circulation 85: 1706-1712, 1992.
5. Baltacioglu F, Afsar N, Ekinci G, Elmaci NT, Cimsit NC, Aktan S, and Erzen C. [Intraarterial thrombolysis in the treatment of acute ischemic stroke: technical and clinical results]. Tani Girisim Radyol 9: 229-239, 2003.
6. Bertolino G, Noris P, Previtali M, Gamba G, Ferrario M, Montani N, and Balduini CL. Platelet function after in vivo and in vitro treatment with thrombolytic agents. Am J Cardiol 69:457- 461, 1992.
7. Black SC, Gralinski MR, Friedrichs GS, Kilgore KS, Driscoll EM, and Lucchesi BR. Cardioprotective effects of heparin or N-acetylheparin in an in vivo model of myocardial ischaemic and reperfusion injury. Cardiovasc Res 29: 629-636, 1995.
8. Bourekas EC, Slivka AP, Shah R, Sunshine J, and Suarez JI. Intraarterial thrombolytic therapy within 3 hours of the onset of stroke. Neurosurgery 54: 39-44, 2004.
9. Chang WC, Shi GY, Chow YH, Chang LC, Hau JS, Lin MT, Jen CJ, Wing LY, and Wu HL. Human plasmin induces a receptor-mediated arachidonate release coupled with G proteins in endothelial cells. Am J Physiol Cell Physiol 264: C271-C281, 1993.
10. Darius H, Yanagisawa A, Brezinski ME, Hock CE, and Lefer AM. Beneficial effects of tissue-type plasminogen activator in acute myocardial ischemia in cats. J Am Coll Cardiol 8: 125-131, 1986.
11. Guan AL, Retzios AD, Henderson GN, and Markland FS Jr. Purification and characterization of a fibrinolytic enzyme from venom of the southern copperhead snake (Agkistrodon contortrix contortrix). Arch Biochem Biophys 289: 197-207, 1991.
12. Heinz HP and Loos M. Activation of the first component of complement, C1: comparison of the effect of sixteen different enzymes on serum C1. Immunobiology 165: 175-185, 1983.
13. Hennan JK, Hong TT, Willens DE, Driscoll EM, Giboulot TA, and Lucchesi BR. Prevention of experimental carotid and coronary artery thrombosis by the glycoprotein IIb/IIIa receptor antagonist CRL42796. Br J Pharmacol 136: 927-937, 2002.
14. Hong TT, Driscoll EM, White AJ, Sherigill A, Giboulot TA, and Lucchesi BR. Glycoprotein IIb/IIIa receptor antagonist (2S)-2-[(2-naphthyl-sulfonyl) amino]-3-[[2-([4-(4-piperidinyl)-2-[2-(4-pipe ridinyl)ethyl]-butanoyl]amino) acetyl]amino]propanoic acid dihydrochloride (CRL42796), in combination with aspirin and/or enoxaparin, prevents coronary artery rethrombosis after successful thrombolytic treatment by recombinant tissue plasminogen activator. J Pharmacol Exp Ther 306: 616-623, 2003.
15. Kloner RA, Alker K, Campbell C, Figures G, Eisenhauer A, and Hale S. Does tissue-type plasminogen activator have direct beneficial effects on the myocardium independent of its ability to lyse intracoronary thrombi? Circulation 79: 1125-1136, 1989.
16. Loos M and Heinz HP. Generation of the classical pathway C3 convertase (EAC4b2a) by proteolytic enzymes. Acta Pathol Microbiol Immunol Scand Suppl 284: 67-74, 1984.
17. Lucchesi BR, Burmeister WE, Lomas TE, and Abrams GD. Ischemic changes in the canine heart as affected by the dimethyl quaternary analog of propranolol, UM-272 (SC-27761). J Pharmacol Exp Ther 199: 310-328, 1976.
18. Lucchesi BR and Kilgore KS. Complement inhibitors in myocardial ischemia/reperfusion injury. Immunopharmacology 38: 27-42, 1997.
19. Lucchesi BR and Tanhehco EJ. Therapeutic potential of complement inhibitors in myocardial ischaemia. Expert Opin Investig Drugs 9: 975-991, 2000.
20. Lupia E, Del Sorbo L, Bergerone S, Emanuelli G, Camussi G, and Montrucchio G. The membrane attack complex of complement contributes to plasmin-induced synthesis of platelet-activating factor by endothelial cells and neutrophils. Immunology 109: 557-563, 2003.
21. Markland FS, Friedrichs GS, Pewitt SR, and Lucchesi BR. Thrombolytic effects of recombinant fibrolase or APSAC in a canine model of carotid artery thrombosis. Circulation 90: 2448-2456, 1994.
22. Merlini PA, Cugno M, Rossi ML, Agricola P, Repetto A, Fetiveau R, Diotallevi P, Canosi U, Mannucci PM, and Ardissino D. Activation of the contact system and inflammation after thrombolytic therapy in patients with acute myocardial infarction. Am J Cardiol 93: 822-825, 2004.
23. Meyners W, Peters S, Trummel M, and Koehler B. Successful recanalization of an occluded coronary artery by percutaneous coronary intervention, systemic administration of tirofiban, a glycoprotein IIb/IIIa inhibitor, and intracoronary thrombolysis with alteplase. Z Kardiol 93: 407-412, 2004.
24. Nagai N, Vanlinthout I, and Collen D. Comparative effects of tissue plasminogen activator, streptokinase, and staphylokinase on cerebral ischemic infarction and pulmonary clot lysis in hamster models. Circulation 100: 2541-2546, 1999.
25. Ouriel K, Cynamon J, Weaver FA, Dardik H, Akers D, Blebea J, Gruneiro L, Toombs CF, Wang-Clow F, Mohler M, Pena L, Wan CY, and Deitcher SR. A phase I trial of alfimeprase for peripheral arterial thrombolysis. J Vasc Interv Radiol 16: 1075-1083, 2005.
26. Parise P, Hauert J, Iorio A, Callegari P, and Agnelli G. Streptokinase and rt-PA activate platelets by a different way: implications on the rethrombosis rate after their administration in myocardial infarction. J Lab Clin Med 125: 212-221, 1995.
27. Penny WF and Ware JA. Platelet activation and subsequent inhibition by plasmin and recombinant tissue-type plasminogen activator. Blood 79: 91-98, 1992.
28. Romeo F, Rosano GM, Martuscelli E, Comito M, Cardona N, Colistra C, Milano B, Bianco C, and Rosano V. Effectiveness of prolonged low dose recombinant tissue-type plasminogen activator for refractory unstable angina. J Am Coll Cardiol 25: 1295-1299, 1995.
29. Romson JL, Haack DW, and Lucchesi BR. Electrical induction of coronary artery thrombosis in the ambulatory canine: a model for in vivo evaluation of anti-thrombotic agents. Thromb Res 17: 841-853, 1980.
30. Ryan TJ, Lai L, and Malik AB. Plasmin generation induces neutrophil aggregation: dependence on the catalytic and lysine binding sites. J Cell Physiol 151: 255-261, 1992.
31. Schafer AI and Adelman B. Plasmin inhibition of platelet function and of arachidonic acid metabolism. J Clin Invest 75: 456-461, 1985.
32. Schafer AI, Maas AK, Ware JA, Johnson PC, Rittenhouse SE, and Salzman EW. Platelet protein phosphorylation, elevation of cytosolic calcium, and inositol phospholipid breakdown in platelet activation induced by plasmin. J Clin Invest 78: 73-79, 1986.
33. Schaiff WT and Eisenberg PR. Direct induction of complement activation by pharmacologic activation of plasminogen. Coron Artery Dis 8: 9-18, 1997.
34. Sudo Y and Lucchesi BR. Antithrombotic effect of GYKI-14766 in a canine model of arterial and venous rethrombosis: a comparison with heparin. J Cardiovasc Pharmacol 27: 545-555, 1996.
35. Syrovets T, Jendrach M, Rohwedder A, Schule A, and Simmet T. Plasmin-induced expression of cytokines and tissue factor in human monocytes involves AP-1 and IKKβ-mediated NF-κB activation. Blood 97: 3941-3950, 2001.
36. Tanhehco EJ, Yasojima K, McGeer PL, McGeer EG, and Lucchesi BR. Preconditioning reduces myocardial complement gene expression in vivo. Am J Physiol Heart Circ Physiol 279: H1157-H1165, 2000.
37. Tanhehco EJ, Yasojima K, McGeer PL, Washington RA, Kilgore KS, Homeister JW, and Lucchesi BR. Preconditioning reduces tissue complement gene expression in the rabbit isolated heart. Am J Physiol Heart Circ Physiol 277: H2373-H2380, 1999.
38. Tiefenbrunn AJ. Intracoronary recombinant tissue-type plasminogen activator (rt-PA). Coron Artery Dis 7: 637-640, 1996.
39. Toombs CF. Alfimeprase: pharmacology of a novel fibrinolytic metalloproteinase for thrombolysis. Haemostasis 31: 141-147, 2001.
40. Topol EJ. Acute myocardial infarction: thrombolysis. Heart 83: 122-126, 2000.
41. Weide I, Tippler B, Syrovets T, and Simmet T. Plasmin is a specific stimulus of the 5-lipoxygenase pathway of human peripheral monocytes. Thromb Haemost 76: 561-568, 1996.
42. Willerson JT and Zoldhelyi P. Future directions in thrombolysis. Clin Cardiol 22: IV44-IV53, 1999.
43. Wilson SH, Bell MR, Rihal CS, Bailey KR, Holmes DR Jr, and Berger PB. Infarct artery reocclusion after primary angioplasty, stent placement, and thrombolytic therapy for acute myocardial infarction. Am Heart J 141: 704-710, 2001.
44. Xue M and Del Bigio MR. Acute tissue damage after injections of thrombin and plasmin into rat striatum. Stroke 32: 2164-2169, 2001.